Global HIV Self-Test Kits Market Size By Test Type (Rapid Test Kits, Laboratory-Based Test Kits), By Sample Type (Blood, Saliva), By Application (Home Testing, Laboratory Testing), By Geographic Scope And Forecast

HIV Self-Test Kits Market Size And Forecast

HIV Self-Test Kits Market size was valued at USD 2.87 Billion in 2024 and is projected to reach USD 19.97 Billion by 2032, growing at a CAGR of 30.29% from 2026 to 2032.

HIV self-test kits represent a significant advancement in HIV prevention and care. HIV self-test kits serve as a valuable asset in combating the HIV epidemic by facilitating early detection and promoting prevention efforts.

These convenient and confidential tools empower individuals to assess their HIV status independently, facilitating early detection and facilitating timely access to medical care.

HIV self-test kits offer greater accessibility to individuals residing in remote or underserved regions, eliminating geographical barriers to testing.

Self-testing empowers individuals to maintain privacy and avoid the potential stigma associated with traditional testing settings.

Early detection of HIV infection through self-testing enables prompt medical intervention, leading to improved health outcomes and reduced transmission risk.

HIV self-test kits generally exhibit high accuracy rates, yet it remains essential to follow the provided instructions meticulously and seek medical consultation for any uncertainties.

HIV self-test kits may not detect recent infections, necessitating follow-up testing with a healthcare provider if necessary.

Global HIV Self-Test Kits Market Dynamics

The key market dynamics that are shaping the global HIV self-test kits market include:

Key Market Drivers

Increasing Prevalence of HIV Worldwide: The rising global HIV prevalence is driving demand for self-test kits. UNAIDS reported 38.4 million people living with HIV worldwide in 2023, a 2% increase from 2022. On January 15, 2024, OraSure Technologies announced the launch of its next-generation OraQuick HIV Self-Test in Southeast Asia, aiming to improve access to testing in high-prevalence regions.

Growing Awareness and Reducing Stigma: Efforts to raise awareness and reduce stigma are boosting self-testing adoption. The WHO reported a 25% increase in HIV self-testing volumes globally in 2023 compared to 2022. On March 3, 2024, the Gates Foundation pledged $50 million to support HIV self-testing awareness campaigns in sub-Saharan Africa, partnering with local health organizations to normalize regular testing.

Innovations in HIV Self-Test Technology: Innovations in HIV self-test kits are improving accuracy and user-friendliness. The FDA approved three new HIV self-test technologies in 2023, enhancing testing options. On February 20, 2024, Abbott Laboratories unveiled a smartphone-connected HIV self-test kit, allowing users to receive digital results and connect with healthcare providers for follow-up care.

Government Initiatives Promoting HIV Self-Testing: Increased government support is expanding access to HIV self-testing. The U.S. Department of Health and Human Services allocated $120 million for HIV self-testing programs in 2023, a 15% increase from 2022. On April 5, 2024, the UK government announced a nationwide free HIV self-test distribution program, aiming to reach 1 million people annually.

Key Challenges:

Limited Awareness and Stigma Hindering Testing Rates: Many individuals at risk for HIV infection may not be aware of the importance of testing or may face stigma associated with HIV, deterring them from seeking testing. Addressing these barriers requires increased public awareness campaigns and efforts to reduce stigma.

Lack of Access to Testing Facilities Hampering Early Diagnosis: Limited availability of testing facilities, particularly in underserved or rural areas, can hinder early diagnosis of HIV infection. Expanding access to testing facilities, including through community-based programs, is crucial for addressing this challenge.

Cost Barriers Obstructing Access to Testing: The cost of HIV self-test kits may be a barrier for some individuals, particularly in low-income communities. This can limit access to testing and prevent early diagnosis. Providing affordable or subsidized testing options can help address this challenge.

Regulatory Hurdles Challenging Market Expansion: Navigating the regulatory landscape for HIV self-test kits can be complex, especially for manufacturers and distributors operating in multiple jurisdictions. Compliance with regulatory requirements can increase costs and hinder market expansion.

Key Trends

Telemedicine Facilitating Remote Testing and Counseling: The growth of telemedicine is facilitating remote HIV testing and counseling. The CDC reported a 40% increase in telehealth consultations following HIV self-tests in 2023. On March 10, 2024, Hologic partnered with Teladoc Health to launch an integrated HIV self-testing and virtual counseling service, providing comprehensive care to users.

Expanding Distribution Channels: Diverse distribution channels are improving access to HIV self-test kits. The WHO reported a 30% increase in pharmacies offering HIV self-test kits in low- and middle-income countries in 2023. On January 30, 2024, Amazon announced the inclusion of FDA-approved HIV self-test kits in its healthcare product line, significantly expanding online access to testing.

Targeted Efforts to Reach Key Populations: Targeted efforts to reach key populations are driving self-test kit adoption. On February 5, 2024, BioSure partnered with LGBTQ+ organizations in Brazil to distribute 100,000 free HIV self-test kits, focusing on improving testing rates in high-risk communities.

Regulatory Support and Streamlined Approvals: Supportive regulations are accelerating market growth. The European Medicines Agency approved five new HIV self-test kits in 2023, streamlining the approval process. On March 25, 2024, the WHO prequalified a new low-cost HIV self-test from Atomo Diagnostics, paving the way for increased access in resource-limited settings and driving global market expansion.

Global HIV Self-Test Kits Market Regional Analysis

Here is a more detailed regional analysis of the global HIV self-test kits market:

North America

North America is dominating the HIV self-test kits market, driven by advanced healthcare infrastructure and strong awareness campaigns.

According to the Centers for Disease Control and Prevention (CDC), HIV self-testing in the United States increased by 35% in 2023 compared to the previous year, with over 2.5 million self-tests distributed.

The region's market leadership is also supported by favorable government policies and innovative public health initiatives.

Health Canada reported that 78% of new HIV diagnoses in 2023 were initially detected through self-testing, highlighting its effectiveness in early detection.

On March 15, 2024, Abbott Laboratories launched a nationwide campaign in collaboration with the U.S. Department of Health and Human Services, aiming to distribute 1 million free HIV self-test kits to underserved communities over the next year.

This initiative, coupled with the increasing integration of self-testing into routine healthcare practices, further solidifies North America's position at the forefront of the global HIV self-test kits market.

Asia-Pacific

The Asia-Pacific region is projected to experience a rapid CAGR growth during the forecast period, driven by the increasing awareness, government initiatives, and improving healthcare access.

According to the World Health Organization's Western Pacific Regional Office, HIV self-testing uptake in the region increased by 62% in 2023 compared to the previous year.

This growth was further accelerated on January 20, 2024, when the Chinese government announced a nationwide program to distribute 5 million free HIV self-test kits annually, partnering with local manufacturer Wondfo Biotech to ensure widespread availability.

The region's market expansion is also fueled by technological advancements and strategic collaborations. India's National AIDS Control Organisation reported a 45% increase in HIV self-testing among high-risk populations in 2023, largely attributed to mobile health initiatives.

On March 5, 2024, Mylan Pharmaceuticals (now part of Viatris) launched a smartphone-connected HIV self-test kit in Southeast Asia, starting with Thailand and Vietnam.

This innovation, coupled with a partnership announced on April 1, 2024, between the Bill & Melinda Gates Foundation and several APAC countries to subsidize self-test kits, underscores the region's potential for continued rapid growth in the HIV self-test kits market.

Global HIV Self-Test Kits Market: Segmentation Analysis

The Global HIV Self-Test Kits Market is segmented based on Test Type, Sample Type, Application, and Geography.

HIV Self-Test Kits Market, By Test Type

• Rapid Test Kits
• Laboratory-Based Test Kits

Based on Test Type, the Global HIV Self-Test Kits Market is bifurcated into Rapid Test Kits, Laboratory-Based Test Kits. The rapid test kits segment maintains a dominant position within the HIV self-test kit market, favored for their convenience, affordability, and ease of use. These tests offer rapid results, enabling prompt decision-making and access to medical care. However, the laboratory-based test kits segment is experiencing rapid growth, driven by their superior sensitivity and specificity, making them indispensable for confirming HIV diagnoses and monitoring viral load.

HIV Self-Test Kits Market, By Sample Type

• Blood
• Saliva
• Urine

Based on Sample Type, the Global HIV Self-Test Kits Market is bifurcated into Blood, Saliva, Urine. The blood segment is dominating the HIV self-test kit market, driven by its high accuracy and reliability in detecting HIV antibodies. However, the saliva segment is experiencing rapid growth, as saliva-based tests offer a less invasive and more convenient option for testing.

HIV Self-Test Kits Market, By Application

• Home Testing
• Point-of-Care Testing
• Laboratory Testing

Based on Application, the Global HIV Self-Test Kits Market is bifurcated into Home Testing, Point-of-Care Testing, Laboratory Testing. The home testing segment is currently dominating the HIV self-test kit market, driven by the convenience and privacy that self-testing offers. However, the point-of-care testing segment is experiencing rapid growth, as healthcare providers are increasingly adopting rapid HIV tests for quick and efficient diagnosis in clinical settings.

HIV Self-Test Kits Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on Geography, the Global HIV Self-Test Kits Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The North American region continues to dominate the global HIV self-test kits market, driven by the advanced healthcare infrastructure and strong awareness campaigns. However, the Asia-Pacific region is projected to experience a rapid CAGR growth during the forecast period, driven by increasing awareness, government initiatives, and improving healthcare access.

Key Players

The "Global HIV Self-Test Kits Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are SD Biosensor, CTK Biotech, Genedrive Plc, Hyrex Diagnostics, Trinity Biotech, Mylan Laboratories, BioSure, PerkinElmer, Acon Laboratories, OraSure Technologies, Vestergaard Frandsen, Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, MP Biomedicals.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global HIV Self-Test Kits Market Key Developments

• In February 2023, Mylab Discovery Solutions, announced the launch of three new rapid kits for the quick and early diagnosis of STIs, including as syphilis, hepatitis C virus, and HIV.
• In November 2022, in an effort to further diagnostic solutions, Chembio Diagnostics applied for a CLIA waiver from the FDA for their DPP HIV-Syphilis System.